| Scibase

Dec 01 2016

SciBase appoints Anna Danström as new head of Production and Supply Chain

SciBase, who in June of this year took over the manufacturing of their single-use electrode from Ginolis, has appointed Anna Danström as Supply Chain & Production Manager. Anna Danström, who previously was responsible for electrode development at SciBase, has recently assumed her new role. As Supply Chain & Production Manager Anna becomes a member of the management team, where she replaces Marko Päivärinne.

The insourcing of manufacturing has resulted in a number of advantages for SciBase, including better conditions to pursue the development of more cost-effective larger-scale manufacturing. With Anna as new Supply Chain & Production Manager the work to streamline and scale the production of electrodes in Uppsala will be intensified.

- The manufacturing of electrodes is our most strategically important process and it is of utmost importance that we can both streamline and increase production capacity going forward, a task which Anna is perfectly suited for. With the addition of Anna and also Niklas Jakobsson, who recently assumed responsibility for Quality Assurance and Regulatory issues, we are creating a very strong management team with the relevant competence and experience, says Simon Grant, CEO of SciBase.

Apart from being responsible for the development of electrodes at SciBase Anna has had long experience within medtech, working for a number of international companies such as St. Jude Medicals where she worked in a number of global technology transfer projects. Anna also has experience in working with FDA-related processes, which will be a benefit given SciBase’s on-going PMA process and the forthcoming launch on the US market. Anna replaces Marko Päivärinne who has decided to pursue new challenges outside the company from early next year.

SciBase’s product Nevisense requires a new electrode for every patient examined. SciBase’s business model is based on selling instruments, but the major potential lies in the continuous use of the instruments, which generates revenues from the sale of the single-use electrodes. During the autumn SciBase passed a milestone of 10,000 electrodes sold during the year and increased sales of the electrodes by 77 percent for the first nine months of the year.

For further information please visit www.scibase.com or contact:

Simon Grant, CEO
Tel: +46 72 887 43 99
E-mail: [email protected]

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on December 1, 2016.

About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.

Dec 22 2016

SciBase ships first delivery of Nevisense View

SciBase’s new instrument Nevisense View combines patented impedance measurement (EIS) for early detection of malignant melanoma with visual information from digital dermoscopy. Today the first Nevisense View instrument leaves SciBase for delivery to Belgium.

The new instrument Nevisense View integrates images from digital dermoscopy with Nevisense’s EIS-technology. The result is that all information from a skin examination is gathered in the same instrument, thus improving clinic workflow. To be able to track the development of a suspicious lesion, with the help of both EIS-values and images, helps prevent unnecessary excision of healthy lesions and minimises the risk of missing malignant melanoma.

Nevisense View is developed together with leading Dermatologists to improve workflow for clinical staff by providing the following functions:

Wireless transfer of images to Nevisense
Combination of EIS results, clinical and dermoscopy images, and patient information in one PDF-report for complete documentation of an examination.
Easy-to-use follow-up functionality, such as split screen comparison of lesions over time.

- A new Australian study, presented in August of this year, showed that the utilisation of EIS can reduce the number of cases that need to undergo sequential digital dermoscopy monitoring by almost half while also detecting most malignant melanomas three months earlier than sequential digital dermoscopy alone. The combination of digital dermoscopy and our unique EIS-measurement in the same instrument is therefore of both significant clinical benefit and can also potentially deliver significant health economic savings, says Simon Grant, CEO of SciBase.

Subscribe to SciBase’s monthly letter from the CEO here.

For further information please visit www.scibase.com or contact:

Simon Grant, CEO
Tel: +46 72 887 43 99
E-mail: [email protected]

About Skin Cancer
Skin cancer is one of the world’s most common cancers, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.

Dec 22 2016

SciBase increases the information flow to shareholders with a regular letter from the CEO

To keep shareholders and other interested parties updated about SciBase progress we have we have decided to start sending out regular short newsletters regarding company activities and market information. In these letters we will explain important events in the Company’s development in a little more detail and touch upon current events within our industry or in the field of skin cancer. Please sign up for this newsletter here.

In this first letter we thought we’d outline our view on one of this autumn’s hot topics - teledermoscopy, and discuss how this method relates to our instrument.

Teledermoscopy – good for increased awareness and access but is it good enough as a diagnostic method?

Cancer is a disease that affects us all. It is estimated that a third of all Swedes will at some time in their lives receive a cancer diagnosis. One of the fastest growing cancers is skin cancer, of which malignant melanoma is the most dangerous type. Our instrument Nevisense, complements a traditional visual examination with a direct physical measurement of a lesion’s structure via its impedance. This helps physicians objectively assess suspicious lesions directly on the skin, i.e. without having to surgically excise the lesion of concern. With the help of Nevisense a physician can potentially detect melanoma at an earlier stage in its development, while decreasing the number of unnecessary surgeries to excise suspicious lesions. The earlier that cancer can be detected the higher the survival rate will be.

In recent times much has been written about teledermoscopy, a method to evaluate suspected skin cancer based on the remote evaluation of lesion images. Teledermoscopy means taking a picture of a suspicious lesion then sending the image and patient’s clinical data to a specialist for interpretation. The patient later receives advice on how to proceed, usually whether or not the patient needs to visit a physician for a ‘physical’ examination.

There are different variants of teledermoscopy. On the consumer (public) market there are apps that can be installed on your smartphone. Through the app you take a picture of a lesion and then send it for interpretation by (usually) a Dermatologist. The assessment usually costs from a few hundred crowns, and you usually receive a response within 24 hours to two weeks.

The healthcare sector has generally also embraced the method, which means that many primary care centers and General Practitioners have the possibility to send a picture to a specialist for assessment. This is something that takes place for example, in Stockholms Läns Landsting. Study results indicate that teledermoscopy results in shorter waiting times compared to the normal wait to see a Dermatologist.

Teledermoscopy improves patient access to an examination and can result in the patient receiving care earlier, which is good. The earlier we detect malignant melanoma the better the chance to treat it successfully. When it comes to teledermoscopy for consumers there is however a risk with patients themselves selecting which lesion or lesions are to be assessed. The risk is that they choose benign lesion(s) for evaluation while missing the lesion that is a melanoma or other type of skin cancer. In addition a recent review published in JAMA Dermatology [1] showed that in general assessment by a Dermatologist during a face to face consultation results in a more accurate assessment than one done by teledermoscopy. It is therefore advantageous for patients to utilise face to face assessment by a physician who performs a full examination.

The products that cater to the consumer do however contribute with an important factor, to increase awareness which can lead to an increased patient flow into the health care system. To be able to handle the increased number of patients with lesions of concern, the health care system needs to be improved and streamlined. This is where SciBase comes in. As greater numbers of suspicious lesions are being evaluated, diagnosis needs to be as efficient and effective as possible. Diagnosis often involves excision of a suspected lesion, yet we know that 93-97 percent of all excisions are unnecessary as the excised tissue is not cancerous. Utilising Nevisense can reduce the number of unnecessary excisions by up to 40 percent. In addition to saving money for the healthcare system by performing fewer operations and pathology evaluations, we reduce patient anxiety and discomfort. Whereas Nevisense provides an immediate answer, excisions and biopsies must be analysed by a pathologist to determine if they are malignant or not. In the worst case it can take up to eight weeks to get an answer, a wait that can be hard on the patient.

Nevisense is therefore a good complement to the diagnostic process both in situations with or without teledermoscopy. The challenge for Scibase is to demonstrate that Nevisense can help streamline the diagnostic process, save money and provide better care to patients. We are well on the way with a number of studies. A recent Australian study shows that Nevisense can halve the number of patients that need to undergo sequential monitoring i.e. that need to have a follow-up visit with digital dermoscopy. This is just one example of how Nevisense can lead to substantial cost-savings.

Launch of Nevisense View

Finally, in response to our customers demand, we are expanding the functionality of Nevisense and launching an additional product – Nevisense View. With Nevisense View we have integrated clinical and dermoscopic images with our patented impedance technology. This new product was developed for clinicians that want to combine both methods and improve the management of patients. The first shipments to customers start now in December 2016. In the next CEO letter we will discuss Nevisense View and its application in more detail.

Merry Christmas and a Happy New Year!

For further information please visit www.scibase.com or contact:

Simon Grant, CEO
Tel: +46 72 887 43 99
E-mail: [email protected]

[1] Finnane A Soyer P et al. Teledermatology for the Diagnosis and Management of Skin Cancer. A Systematic Review. JAMA Dermatology. Dec. 2016

Oct 31 2016

The following people have been appointed as members of SciBase Holding's election committee for the Annual General Meeting in 2017:

David Sonnek (representing SEB Venture Capital and SEB pensionsstiftelse),

Per Nordberg (Fouriertransform),

Renee Aguiar-Lucander (Omega fund IV L.P.),

Tord Lendau (Chairman of the Board).

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of SciBase Holding on May 16, 2016.

The Annual General Meeting of SciBase Holding AB (publ) will be held on May 16, 2017 in Stockholm.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Stockholm, October 31, 2016

SciBase Holding AB (publ)

For more information, please contact:
Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67

Michael Colérus, CFO, phone +46 70 341 34 72

About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.

Nov 14 2016

Interim Report

January 1 – September 30, 2016

The third quarter in figures

Total net sales amounted to TSEK 1,580 (995).
The loss after tax amounted to TSEK 12,395 (10,260).
The loss per share amounted to SEK 1.50 (1.24).
The cash flow from current operations was negative in the amount of TSEK 10,459 (9,669).
Significant margin improvement with gross margin increasing to 44.6% in Q3 (17.6%).

The first nine months in figures

Total net sales amounted to TSEK 4,501 (2,970).
The loss after tax amounted to TSEK 38,463 (30,378).
The loss per share amounted to SEK 4.64 (4.71).
The cash flow from current operations was negative in the amount of TSEK 34,818 (32,724).
Significant margin improvement with gross margin increasing to 34.3% (-3.8%).

Important events during the quarter

A milestone was passed on the German market as the 100th customer bought and installed a Nevisense device. Our primary market Germany continues to show good growth with total sales up by 67% and electrode sales volume up by 118% in the quarter.
In the period SciBase introduced its new product – Nevisense View – combining SciBase’s patented electrical impedance spectroscopy (EIS) for early detection of malignant melanoma with visual information from digital dermoscopy, creating a complete instrument that improves and simplifies the diagnostic process.
In the period a new Australian study was presented, which showed that by using Nevisense, it is possible to reduce the number of cases that require digital dermoscopy follow-up by almost half. In addition Nevisense detected most melanoma three months earlier than traditional methods. The study consisted of 118 patients with 160 lesions, and the results were presented for the first time at the World Congress on Cancers of the Skin in Vienna on September 1.
Significant resources allocated during the quarter on the PMA-process, with continued progress. Ongoing work to provide replies to feedback from the FDA within several areas. We have passed the inspection phase and no additional clinical data have been requested so far.

Important events after the end of the period

A nominating committee has been appointed for the AGM 2017.

Financial overview

					Oct 1 2015 -
	July 1 - Sep 30		Jan 1 - Sep 30		Sep 30 2016	Jan 1 - Dec 31
THE GROUP	2016	2015	2016	2015	Rolling-12	2015
Net sales, SEK ths	1 580	995	4 501	2 970	5 682	4 151
Gross margin, %	44,6%	17,6%	34,3%	-3,8%	31,0%	2,5%
Equity/Asset ratio, %	91,3%	94,2%	91,3%	94,2%	91,3%	95,1%
Net indebtness, multiple	0,09	0,06	0,09	0,06	0,09	0,05
Cash equivalents, SEK ths	98 272	147 661	98 272	147 661	98 272	133 736
Cashflow from operating activities, SEK ths	-10 459	-9 669	-34 818	-32 724	-48 682	-46 588
Earnings per share (before and after dilution), SEK*	-1,50	-1,24	-4,64	-4,71	-5,99	-6,01
Shareholder's equity per share, SEK*	12,96	18,93	12,96	24,31	12,96	21,09
Average number of shares, 000'*	8 285	8 285	8 285	6 451	8 285	6 910
Number of shares at closing of period, 000'*	8 285	8 285	8 285	8 285	8 285	8 285
Share price at end of period, SEK	25,20	30,80	25,20	30,80	25,20	31,00
Average number of employees	22	15	21	14	18	14
*Adjusted for in May 2015 performed reversed split, 40:1

Nov 22 2016

SciBase strengthens its management team with Niklas Jakobsson

SciBase has recently taken over the production of its single use electrodes and is moving towards a launch of Nevisense on the US market. As part of this process, the Company has chosen to strengthen the management team with Niklas Jakobsson who is responsible for the Company’s Quality management system and Regulatory issues.

Niklas previously held the position of Quality manager at Ginolis AB in Uppsala where the electrode was manufactured before it was transferred to SciBase. This and his experience with the US market makes him a natural addition to the management team.

Niklas brings a wealth of other experience to SciBase with almost 20 years working in the MedTech industry. He has held positions within R&D, Production and Quality management for a number of different MedTech companies; many of which have been active on the US market.

For more information, please contact:
Simon Grant, CEO
Phone: +46 72 887 43 99
Email: [email protected]

Aug 19 2016

Interim Report

January 1 – June 30, 2016

The second quarter in figures

Total net sales amounted to TSEK 1,855 (918).
The loss after tax amounted to TSEK 14,468 (10,939).
The loss per share amounted to SEK 1.75 (1.80).
The cash flow from current operations was negative in the amount of TSEK 13,112 (13,858).
Significant margin improvement with gross margin increasing to 30.1% in Q2 (-34.5% Q2 15).

The first half-year in figures

Total net sales amounted to TSEK 2,921 (1,975).
The loss after tax amounted to TSEK 26,068 (20,118).
The loss per share amounted to SEK 3.15 (3.63).
The cash flow from current operations was negative in the amount of TSEK 24,359 (23,055).
Significant margin improvement with gross margin increasing to 28.7% (-14.6%).

Important events during the quarter

Record growth in key market Germany with total sales up 124% and electrode sales volume up 212%.
SciBase will insource the strategically important production of the disposable electrode from Ginolis. The companies have mutually agreed to transfer the manufacturing to SciBase when Ginolis AB has completed the next milestone in the stepwise automation of the production process.
As part of the Nevisense PMA-process, a series of inspections were carried out by the US FDA with good results.
The AGM was held on May 16, 2016.
SciBase participated in the Euromelanoma week May 9-13, a European initiative to highlight skin-cancer.
On April 25th, the Annual Report for 2015 was published.

Important events after the end of the period

A milestone was passed when the hundredth clinic in Germany installed a Nevisense device.

Financial overview

					Jul 1 2015 -
	Apr 1 - June 30		Jan 1 - June 30		Jun 30 2016	Jan 1-Dec 31
THE GROUP	2016	2015	2016	2015	Rolling-12	2015
Net sales, SEK ths	1 855	918	2 921	1 975	5 097	4 151
Gross margin, %	30,1%	-34,5%	28,7%	-14,6%	24,1%	2,5%
Equity/Asset ratio, %	92,7%	91,4%	92,7%	91,4%	92,7%	95,1%
Net indebtness, multiple	0,08	0,09	0,08	0,09	0,08	0,05
Cash equivalents, SEK ths	108 786	165 595	108 786	165 595	108 786	133 736
Cashflow from operating activities, SEK ths	-13 112	-13 858	-24 359	-23 055	-47 892	-46 588
Earnings per share (before and after dilution), SEK*	-1,75	-1,80	-3,15	-3,63	-5,73	-6,01
Shareholder's equity per share, SEK*	14,45	27,41	14,45	30,13	14,45	21,09
Average number of shares, 000'*	8 285	6 085	8 285	5 535	8 285	6 910
Number of shares at closing of period, 000'*	8 285	8 285	8 285	8 285	8 285	8 285
Share price at end of period, SEK	17,20	43,00	17,20	43,00	17,20	31,00
Average number of employees	19	13	19	14	15	14
*Adjusted for in May 2015 performed reversed split, 40:1

Aug 26 2016

New Study: Swedish Nevisense can reduce follow-up visits by half for difficult-to-diagnose lesions in melanoma detection

A new Australian study, using the Swedish instrument Nevisense, showed it is possible to reduce the number of cases that require digital dermoscopy follow-up by almost half. In addition Nevisense detected most melanoma three months earlier than traditional methods. Nevisense thereby constitutes a valuable complement to a visual exam with a dermatoscope. The study consisted of 118 patients with 160 lesions, and the results will be presented for the first time at the World Congress on Cancers of the Skin in Vienna on September 1.

Malignant melanoma is often difficult to detect, and early detection is of crucial importance. Lesions suspected of being malignant melanoma, but which cannot be clearly determined during the initial examination, are followed up in many cases with the help of what is known as short term digital dermoscopy imaging (SDDI), which means that the lesion is photographed and compared over time.

The use of SDDI is increasing – especially in difficult-to-diagnose cases – but it is resource-intensive and can take three months or more for a final diagnosis. In addition, it can be challenging to get patients to return for follow-up visits.

In the new Australian study, conducted by Dr Lilian Rocha, Associate Prof. Pascale Guitera, Prof. Scott W. Menzies et. al. at the Melanoma Institute of Australia and Royal Prince Alfred Hospital in Sydney, SDDI was combined with Nevisense’s electrical impedance spectroscopy (EIS) measurement with the following results:

19% of all examined lesions showed a Nevisense EIS value of seven or more and were surgically removed immediately. 83.1% of the malignant melanoma in the study was discovered by Nevisense three months earlier than what SDDI would have allowed.
28% showed a Nevisense EIS value of three or less, which would have made the need for a patient follow-up visit unnecessary.
The combination of SDDI and Nevisense detected 100% of all malignant melanoma in the study.

In total, the use of Nevisense showed the potential to reduce the number of cases that needed to undergo SDDI by 47%. This could simplify diagnostics and lead to significant cost savings for health care while shortening patients’ waiting time for a diagnosis.

“The cases in the study involve difficult-to-diagnose lesions, and the current diagnostic process is time consuming for both clinicians and patients. This study result is very important because it shows the potential for Nevisense to improve the process - saving both time and resources in the healthcare sector” says Simon Grant, CEO at SciBase.

For more information, please contact:
Simon Grant, CEO
Phone: +46 72 887 43 99
Email: [email protected]

Aug 31 2016

SciBase introduces Nevisense View - integrating images in the fight against malignant melanoma

With its new instrument, Nevisense View, SciBase combines its patented electrical impedance spectroscopy (EIS) for early detection of malignant melanoma with visual information from digital dermascopy, creating a complete instrument that can both improve and simplify the diagnostic process.

Malignant melanoma is the most threatening form of skin cancer and is behind 75 percent of all skin cancer deaths. The key to successful treatment of malignant melanoma is early discovery, since this aggressive form of cancer can quickly spread throughout the body. The cancer is often difficult to detect, and digital dermascopy is one of the methods used for detection. This method is based on visual evaluations of skin lesions using a dermascope, while hard-to-diagnose cases often make use of short term digital dermoscopy imaging (SDDI) to compare pictures of lesions that have changed over time.

SciBase is now integrating the digital dermascopy method into its new product and combining it with EIS technology, which uses electrical impulses to detect abnormal cell structures that could be a sign of malignant melanoma. Furthermore, SciBase’s new instrument also simplifies the process for performing skin examinations since all information from the exam is saved in the same instrument. The ability to track the changes of a suspicious lesion, both using EIS values and images, helps prevent both the unnecessary removal of benign tissue and helps avoid malignant melanoma going undetected during an examination.

“According to a new study, conducted by researchers from Melanoma Institute of Australia and Royal Prince Alfred Hospital in Sydney, the use of EIS can reduce the number of cases that need to be followed up using SDDI by almost half, and may also allow for early detection of malignant melanoma three months earlier than traditional methods,” says Simon Grant, CEO of SciBase.

“Being able to combine these two methods into one product and present it in conjunction with a study that supports our method at the World Congress on Cancers of the Skin in Vienna on August 31 is of course a milestone in the company’s history,” says Simon.

Nevisense View simplifies caregivers’ work by offering the following functions:

Wireless transfer of images to Nevisense
Combination of EIS, image and patient information as a PDF report for full documentation of the examination.
Easy-to-use follow-up functions, such as a shared screen for being able to compare lesions over time.

Nevisense View will be available in Sweden and in SciBase’s other markets in November. More information about the study can be found here: Swedish Nevisense can reduce follow up visits by half for difficult-to-diagnose skin changes in melanoma detection

For more information, please contact:

Simon Grant, CEO
Phone: +46 72 887 43 99
Email: [email protected]

Sep 07 2016

SciBase strengthens its management team with Marko Päivärinne

In June SciBase took over production of single-use electrodes from Ginolis, and as a result the company has chosen to strengthen its management team with Marko Päivärinne. Päivärinne is the company’s Production and Logistics Manager and has worked at SciBase since August 2015.

Aside from the fact that SciBase will have full control over production and thereby better conditions for making it more cost-efficient in the future, the integration of electrode manufacturing means that product development will be easier. Marko Päivärinne will be a part of the management team to help bring additional focus to these aspects of manufacturing.

“Electrode production is strategically our most important process, and it will continue to be of great value to us. Therefore, it is very natural for Marko to be a part of the management team. An important part of our work right now is about increasing the volume of electrodes that are being produced using the semi-automated process that Ginolis developed for us,” says Simon Grant, CEO at SciBase.

During the past year, Marko has worked to streamline the supply chain, and has focused on reducing purchasing costs for the components included in electrode manufacturing in order to improve margins – work that he will continue.

Marko has twelve years of experience from the medical technology company Arthrocare Medical Corporation, where he worked with supply chain management and demand planning in addition to implementing business systems. He has also been responsible for managing a number of international acquisitions.

SciBase’s product Nevisense requires a new electrode for every patient examined. SciBase’s business model is based on selling instruments, but the major potential lies in the continuous use of the instruments, which generates revenues from the sale of the single-use electrodes. During the second quarter of 2016 SciBase increased sales of the electrodes by 212 percent in Germany, the company’s primary market.

For more information, please contact:
Simon Grant, CEO
Phone: +46 72 887 43 99
Email: [email protected]

Subscribe to